Month: December 2021

Channelchek Small-Cap Recap 2021-12-20

Posted on by Admin

 

Channelchek Small-Cap Recap

 

Stocks Trending Today:

 

SOPA +251% (1:30pm) 111M volume 8.9M Float

Society Pass, Inc. (NASDAQ: SOPA) shares skyrocketed to $11.79 after the company was added to the Russell 2000 Index effective today. Society Pass went public Nov. 9, and since then, its shares have hit an intraday low of $3.27, and an intraday high of $77.34. The Russell 2000 Index measures the performance of the small-cap segment of the US equity market, and membership is based on membership in the broad market Russell 3000 Index.

 

CANF +65% (1:30pm) 144M volume 20.0M Float

Can Fite Biopharma Ltd. (NYSE: CANF) shares were up to $2.3050 after the company announced a liver cancer patient was cleared of all cancer lesions. The patient has now survived five years, during which time the clinical benefits of treatment have included the disappearance of ascites, normal liver function, and the disappearance of peritoneal carcinomatosis leading to complete clearance of all cancer lesions.

 


Ticker
% Gain
Shares Float
Volume (as of 1:30pm)
SOPA +251% 8.9M 111M
CANF +65% 20.0M 144M

 

Stem Holdings (STMH)(STEM:CA) – What Do Friday’s Announcements Mean?

Posted on by Admin

Monday, December 20, 2021

Stem Holdings (STMH)(STEM:CA)
What Do Friday’s Announcements Mean?

Stem Holdings Inc is engaged in the purchasing, improving, and leasing of properties and finance assets which are operated by third parties and are used for the cultivation and retail sale of marijuana. Its properties includes 42nd Street, and Mulino Farm which are used for agriculture. The company generates its revenue in the form of rental income from tenants.

Joe Gomes, Senior Research Analyst, Noble Capital Markets, Inc.

Joshua Zoepfel, Research Associate, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

    New Direction. After the market close on Friday, Stem Holdings announced it is divesting Driven Deliveries, the e-commerce and delivery platform that was acquired about twelve months ago. According to the press release, the move is a reflection of significantly increased competition in the key California market and reduced price per pound for cannabis, resulting in a consistent low margin business.

    Management Changes.  In addition, Adam Berk resigned as CEO, effective immediately. Co-founder and current CFO Steve Hubbard has been named interim CEO. Mr. Berk’s resignation comes on the heels of the late November departure of COO Ellen Deutsch …



This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary.  Proper due diligence is required before making any investment decision. 

Tapering and What you Need to Know

Posted on by Admin 


	Image Credit: Rafael Saldana (Flickr)

What is the Fed Taper? An Economist Explains How the Fed Withdraws Stimulus

 

Tapering refers to the Federal Reserve policy of unwinding the massive purchases of Treasury bonds and mortgage-backed securities it’s been making to shore up the economy during the pandemic. The unconventional monetary policy of buying assets is commonly known as quantitative easing. The Fed first adopted this policy during the 2008 financial crisis.

Normally, when a central bank wants to reduce the cost of borrowing for companies and consumers, it lowers its target short-term interest rate. But with its target rate at zero during the 2008 crisis – at the same time that there was no inflation and the economy was still hurting – the Fed was no longer able to cut rates further. And so the Fed turned to quantitative easing as a way to continue to reduce borrowing costs. When the government buys assets, their prices go up, which lowers their yield or interest rate.

The Fed again adopted this policy in March 2020 after the COVID-19 pandemic resulted in a national lockdown. By November 2021, the Fed had bought over US$4 trillion worth of Treasuries and other securities.

The U.S. central bank began tapering in November 2021, scaling back total purchases by $15 billion a month, from $120 billion to $105 billion. The Fed decided to double the pace at which it tapers on Dec. 15. Rather than $15 billion, the Fed will reduce purchases by $30 billion every month. At that pace it will no longer be purchasing new assets by early 2022.

 

Why it Matters

Growing concerns among economists that rising inflation could harm the economy are likely a big part of what led the Fed to begin tapering.

Inflation is the rate of change in the price of goods and services. The Consumer Price Index, which includes several categories of everyday items that a typical American might buy, is the measure of inflation most often reported in the media. In November 2021, it was up 6.8% from a year earlier.

By any measure, inflation is above the Fed’s target of 2%. By tapering asset purchases, the Fed may help reduce inflation – or at least slow its rise – because it is withdrawing some of the monetary stimulus that is fueling economic growth.

The reason the Fed has decided to accelerate the process is likely because it now believes inflation may be less transitory than it had hoped, at the same time that the labor market appears strong.

 

What this Means for You

Americans have enjoyed rock-bottom interest rates for the better part of the past 13 years, helping to make it cheaper to borrow money to buy cars and homes and start businesses.

Consumers and companies are already beginning to see slightly higher rates on mortgages, business loans and other types of borrowing.

In other words, the era of cheap money may finally be coming to an end. Enjoy it while it lasts.

 

This article was republished with permission from   The Conversation, a news site dedicated to sharing ideas from academic experts. It represents the research-based findings and thoughts of 
Edouard Wemy Assistant Professor of Economics, Clark University

 

Suggested Reading:



Inflation Seems Persistent, What Now?

Deflation Not Inflation is Risk Says Cathie Wood





Investing in U.S. Maritime Infrastructure Spending

The Detrimental Impact of Fed Policy on Savers

 

 

 

Stay up to date. Follow us:

 

Be Best Blockchain – Melania Trump’s NFTs

Posted on by Admin 


	Image Source: Melania Trump Facebook

Melania Trump Moves into NFT Market to Further “Be Best” Goals

 

Melania Trump announced Thursday (December 16) that she has been eyeballing the NFT art business. She will be offering her first non-fungible token, Melania’s Vision, through December 31st on Solana. Melania joins other celebrities like Tiger Woods, Ellen DeGeneres and Snoop Dogg that have dabbled in this Blockchain medium.

In her official statement, the former first lady said, “I am proud to announce my new NFT endeavor, which embodies my passion for the arts, and will support my ongoing commitment to children through my Be Best initiative.”  She confirmed in her statement that she is starting a platform that will “release NFTs in regular intervals.

 

Trump’s first NFT will be available for purchase until Dec. 31. The NFT, titled “Melania’s Vision,” was first created in watercolor paint and depicts Mrs. Trump’s eyes. It is priced at one SOL, a cryptocurrency that runs on the Solana blockchain, currently valued at around $180. The image will also include an audio recording, a “message of hope” from Melania Trump.

A portion of the proceeds from the NFT sales will “assist children aging out of the foster care system by way of economic empowerment and with expanded access to resources needed to excel in the fields of computer science and technology,” the statement said. The former first lady introduced the Be Best initiative in 2018, during her husband’s term in office. It initially focused on three main “pillars,” well-being, social media use, and opioid abuse among children.

Some of the more high-profile NFTs after Beeple’s The First 5000 Days made headlines include: Jack Dorsey’s digital version of his first tweet, which sold as an NFT for more than $2.9 million, and the viral 2007 video “Charlie Bit My Finger” fetched more than $760,000 in May. Earlier this week, a previously unheard demo track Whitney Houston recorded at age 17, sold as an NFT for $999,999.

 

Suggested Reading:



Trump Media SPAC Merger Details

Tradestation and Trump Media aren’t the Only Hot SPAC Stories





NFT Fractional Ownership and Metaverse Museums

NFT Collectible Marketplace for DRAFTKINGS

 

Sources:

https://melaniatrump.com/eyes-nft

https://explorer.solana.com/address/7CC4YrazfBqr2FMEWEar1fmbP3kULzMfrvW8KDPtfT6W

https://twitter.com/MELANIATRUMP/status/1471468919810670603/photo/1

https://www.lofficielusa.com/pop-culture/celebrities-on-the-crypto-art-craze

https://finance.yahoo.com/news/latest-nft-art-melania-trumps-224641936.html

 

Stay up to date. Follow us:

 

Helius Medical Technologies, Inc. Partners with the Medical University of South Carolina in Pilot Trial on Stroke

Posted on by Admin



Helius Medical Technologies, Inc. Partners with the Medical University of South Carolina in Pilot Trial on Stroke

Research, News, and Market Data on Helius Medical Technologies

 

NEWTOWN, Pa., Dec. 17, 2021 (GLOBE NEWSWIRE) — Helius Medical Technologies, Inc. (Nasdaq:HSDT) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, today announced its partnership with Dr. Steve Kautz, on an investigator-initiated study, conducted at the Medical University of South Carolina (“MUSC”), to evaluate cranial-nerve non-invasive neuromodulation (“CN-NINM”) and dynamic balance in chronic stroke survivors. As part of the study, some patients will receive CN-NINM, which will be delivered using PoNS therapy.

“Falls are a major post-stroke complication and developing an optimal rehabilitation program to improve dynamic balance is critical for reducing stroke related morbidity and economic burdens,” stated Steve Kautz, Ph.D., Chair, Department of Health Sciences and Research, College of Health Professions, MUSC. “Our study aims to evaluate the effects of PoNS therapy on the recovery of gait and postural stability and, in teaming with Helius, we hope to provide a framework for an innovative rehabilitation protocol.”

“MUSC is at the forefront of research in rehabilitation for stroke and other disabling neurologic conditions and we are delighted to support this pilot trial in stroke with our PoNS devices,” said Antonella Favit-Van Pelt, M.D., Ph.D., Helius’ Chief Medical Officer. “Now that the FDA has granted Breakthrough Designation to PoNS for the treatment of dynamic gait and balance deficits in patients with stroke, this collaboration will provide important information to inform our clinical research and upcoming registrational program, allowing us to observe the functional outcomes of PoNS therapy in stroke patients in a real-world clinical setting. We look forward to working with Dr. Kautz and MUSC on this and future studies.”

The study will be a placebo-controlled experimental design in which stroke survivors will participate in balance and gait training for 3 sessions per week, 40 minutes per session, for 4 weeks. MUSC anticipates enrolling twelve participants beginning in early 2022.

About MUSC 

Founded in 1824 in Charleston, MUSC is home to the oldest medical school in the South as well as the state’s only integrated academic health sciences center, with a unique charge to serve the state through education, research and patient care. Each year, MUSC educates and trains more than 3,000 students and nearly 800 residents in six colleges: Dental Medicine, Graduate Studies, Health Professions, Medicine, Nursing and Pharmacy. MUSC brought in more than $328 million in biomedical research funds in fiscal year 2021, continuing to lead the state in obtaining this funding. For information on academic programs, visit www.musc.edu.

As the clinical health system of the Medical University of South Carolina, MUSC Health is dedicated to delivering the highest quality and safe patient care while training generations of compassionate, competent health care providers to serve the people of South Carolina and beyond. Close to 25,000 care team members provide care for patients at 14 hospitals with approximately 2,500 beds and 5 additional hospital locations in development, more than 300 telehealth sites and nearly 750 care locations situated in the Lowcountry, Midlands, Pee Dee and Upstate regions of South Carolina. In 2021, for the seventh consecutive year, U.S. News & World Report named MUSC Health the No. 1 hospital in South Carolina. To learn more about clinical patient services, visit www.muschealth.org.

MUSC and its affiliates have collective annual budgets of $4.4 billion. The more than 25,000 MUSC team members include world-class faculty, physicians, specialty providers and scientists who deliver groundbreaking education, research, technology and patient care.

About Helius Medical Technologies, Inc.

Helius Medical Technologies is a leading neurotech company in the medical device field focused on neurologic deficits using non-implantable platform technologies that amplify the brain’s ability to compensate and promotes neuroplasticity, aiming to improve the lives of people dealing with neurologic diseases. The Company’s first commercial product is the Portable Neuromodulation Stimulator (PoNS). For more information, visit www.heliusmedical.com.

About the PoNS Device and PoNS Therapy

The Portable Neuromodulation Stimulator (PoNS) is an innovative non-surgical medical device, inclusive of a controller and mouthpiece, which delivers electrical stimulation to the surface of the tongue to improve balance and gait. The PoNS device is indicated for use in the United States as a short-term treatment of gait deficit due to mild-to-moderate symptoms from multiple sclerosis (“MS”) and is to be used as an adjunct to a supervised therapeutic exercise program in patients 22 years of age and over by prescription only. Helius is advancing PoNS post-approval research in MS through a recently launched Therapeutic Experience Program (TEP) designed to partner with neurologists and neurorehabilitation therapists at 10-12 US centers of excellence, who express an interest in becoming “early adopters” of PoNS therapy.

PoNS is also authorized for sale in Canada for two indications: (i) PoNS is authorized as a short-term treatment (14 weeks) of chronic balance deficit due to mild-to-moderate traumatic brain injury (“mmTBI”) and is to be used in conjunction with physical therapy; and (ii) PoNS is authorized for use as a short term treatment (14 weeks) of gait deficit due to mild and moderate symptoms from MS and is to be used in conjunction with physical therapy. PoNS is also authorized for sale in Australia for short term use by healthcare professionals as an adjunct to a therapeutic exercise program to improve balance and gait.

Cautionary Disclaimer Statement

Certain statements in this news release are not based on historical facts and constitute forward-looking statements or forward-looking information within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and Canadian securities laws. All statements other than statements of historical fact included in this news release are forward-looking statements that involve risks and uncertainties. Forward-looking statements are often identified by terms such as “believe,” “expect,” “continue,” “will,” “goal,” “aim” and similar expressions. Such forward-looking statements include, among others, statements regarding expected enrollment, timing and other details of the investigator-initiated study, its ability to provide a framework for an innovative rehabilitation protocol and important information to inform the clinical research and upcoming registrational program, expected enrollment, patient participation, centers of excellence and other details of the TEP study and expected time to begin commercialization of the PoNS device in the U.S.

There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those expressed or implied by such statements. Important factors that could cause actual results to differ materially from the Company’s expectations include uncertainties associated with the Company’s capital requirements to achieve its business objectives, the impact of the COVID-19 pandemic, the Company’s ability to train physical therapists in the supervision of the use of the PoNS Treatment, the Company’s ability to secure contracts with rehabilitation clinics, the Company’s ability to obtain national Medicare coverage and to obtain a reimbursement code so that the PoNS device is covered by Medicare and Medicaid, the Company’s ability to build internal commercial infrastructure, secure state distribution licenses, build a commercial team and build relationships with Key Opinion Leaders, neurology experts and neurorehabilitation centers, market awareness of the PoNS device, future clinical trials and the clinical development process, manufacturing and supply chain risks, the product development process and FDA regulatory submission review and approval process, other development activities, ongoing government regulation, and other risks detailed from time to time in the “Risk Factors” section of the Company’s Annual Report on Form 10-K for the year ended December 31, 2020, its Quarterly Report on Form 10-Q for the quarter ended September 30, 2021 and its other filings with the United States Securities and Exchange Commission and the Canadian securities regulators, which can be obtained from either at www.sec.gov or www.sedar.com.

The reader is cautioned not to place undue reliance on any forward-looking statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company assumes no obligation to update any forward-looking statement or to update the reasons why actual results could differ from such statements except to the extent required by law.

Investor Relations Contact

Lisa M. Wilson, In-Site Communications, Inc.
T: 212-452-2793
E: lwilson@insitecony.com

QuickChek – December 17, 2021

Posted on by Admin



Helius Medical Technologies, Inc. Partners with the Medical University of South Carolina in Pilot Trial on Stroke

Helius Medical Technologies announced its partnership with Dr. Steve Kautz, on an investigator-initiated study, conducted at the Medical University of South Carolina

Research, News & Market Data on Helius Medical

Watch recent presentation from Helius Medical

 

Stay up to date. Follow us:

 

Release – Helius Medical Technologies Inc. Partners with the Medical University of South Carolina in Pilot Trial on Stroke

Posted on by Admin



Helius Medical Technologies, Inc. Partners with the Medical University of South Carolina in Pilot Trial on Stroke

Research, News, and Market Data on Helius Medical Technologies

 

NEWTOWN, Pa., Dec. 17, 2021 (GLOBE NEWSWIRE) — Helius Medical Technologies, Inc. (Nasdaq:HSDT) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, today announced its partnership with Dr. Steve Kautz, on an investigator-initiated study, conducted at the Medical University of South Carolina (“MUSC”), to evaluate cranial-nerve non-invasive neuromodulation (“CN-NINM”) and dynamic balance in chronic stroke survivors. As part of the study, some patients will receive CN-NINM, which will be delivered using PoNS therapy.

“Falls are a major post-stroke complication and developing an optimal rehabilitation program to improve dynamic balance is critical for reducing stroke related morbidity and economic burdens,” stated Steve Kautz, Ph.D., Chair, Department of Health Sciences and Research, College of Health Professions, MUSC. “Our study aims to evaluate the effects of PoNS therapy on the recovery of gait and postural stability and, in teaming with Helius, we hope to provide a framework for an innovative rehabilitation protocol.”

“MUSC is at the forefront of research in rehabilitation for stroke and other disabling neurologic conditions and we are delighted to support this pilot trial in stroke with our PoNS devices,” said Antonella Favit-Van Pelt, M.D., Ph.D., Helius’ Chief Medical Officer. “Now that the FDA has granted Breakthrough Designation to PoNS for the treatment of dynamic gait and balance deficits in patients with stroke, this collaboration will provide important information to inform our clinical research and upcoming registrational program, allowing us to observe the functional outcomes of PoNS therapy in stroke patients in a real-world clinical setting. We look forward to working with Dr. Kautz and MUSC on this and future studies.”

The study will be a placebo-controlled experimental design in which stroke survivors will participate in balance and gait training for 3 sessions per week, 40 minutes per session, for 4 weeks. MUSC anticipates enrolling twelve participants beginning in early 2022.

About MUSC 

Founded in 1824 in Charleston, MUSC is home to the oldest medical school in the South as well as the state’s only integrated academic health sciences center, with a unique charge to serve the state through education, research and patient care. Each year, MUSC educates and trains more than 3,000 students and nearly 800 residents in six colleges: Dental Medicine, Graduate Studies, Health Professions, Medicine, Nursing and Pharmacy. MUSC brought in more than $328 million in biomedical research funds in fiscal year 2021, continuing to lead the state in obtaining this funding. For information on academic programs, visit www.musc.edu.

As the clinical health system of the Medical University of South Carolina, MUSC Health is dedicated to delivering the highest quality and safe patient care while training generations of compassionate, competent health care providers to serve the people of South Carolina and beyond. Close to 25,000 care team members provide care for patients at 14 hospitals with approximately 2,500 beds and 5 additional hospital locations in development, more than 300 telehealth sites and nearly 750 care locations situated in the Lowcountry, Midlands, Pee Dee and Upstate regions of South Carolina. In 2021, for the seventh consecutive year, U.S. News & World Report named MUSC Health the No. 1 hospital in South Carolina. To learn more about clinical patient services, visit www.muschealth.org.

MUSC and its affiliates have collective annual budgets of $4.4 billion. The more than 25,000 MUSC team members include world-class faculty, physicians, specialty providers and scientists who deliver groundbreaking education, research, technology and patient care.

About Helius Medical Technologies, Inc.

Helius Medical Technologies is a leading neurotech company in the medical device field focused on neurologic deficits using non-implantable platform technologies that amplify the brain’s ability to compensate and promotes neuroplasticity, aiming to improve the lives of people dealing with neurologic diseases. The Company’s first commercial product is the Portable Neuromodulation Stimulator (PoNS). For more information, visit www.heliusmedical.com.

About the PoNS Device and PoNS Therapy

The Portable Neuromodulation Stimulator (PoNS) is an innovative non-surgical medical device, inclusive of a controller and mouthpiece, which delivers electrical stimulation to the surface of the tongue to improve balance and gait. The PoNS device is indicated for use in the United States as a short-term treatment of gait deficit due to mild-to-moderate symptoms from multiple sclerosis (“MS”) and is to be used as an adjunct to a supervised therapeutic exercise program in patients 22 years of age and over by prescription only. Helius is advancing PoNS post-approval research in MS through a recently launched Therapeutic Experience Program (TEP) designed to partner with neurologists and neurorehabilitation therapists at 10-12 US centers of excellence, who express an interest in becoming “early adopters” of PoNS therapy.

PoNS is also authorized for sale in Canada for two indications: (i) PoNS is authorized as a short-term treatment (14 weeks) of chronic balance deficit due to mild-to-moderate traumatic brain injury (“mmTBI”) and is to be used in conjunction with physical therapy; and (ii) PoNS is authorized for use as a short term treatment (14 weeks) of gait deficit due to mild and moderate symptoms from MS and is to be used in conjunction with physical therapy. PoNS is also authorized for sale in Australia for short term use by healthcare professionals as an adjunct to a therapeutic exercise program to improve balance and gait.

Cautionary Disclaimer Statement

Certain statements in this news release are not based on historical facts and constitute forward-looking statements or forward-looking information within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and Canadian securities laws. All statements other than statements of historical fact included in this news release are forward-looking statements that involve risks and uncertainties. Forward-looking statements are often identified by terms such as “believe,” “expect,” “continue,” “will,” “goal,” “aim” and similar expressions. Such forward-looking statements include, among others, statements regarding expected enrollment, timing and other details of the investigator-initiated study, its ability to provide a framework for an innovative rehabilitation protocol and important information to inform the clinical research and upcoming registrational program, expected enrollment, patient participation, centers of excellence and other details of the TEP study and expected time to begin commercialization of the PoNS device in the U.S.

There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those expressed or implied by such statements. Important factors that could cause actual results to differ materially from the Company’s expectations include uncertainties associated with the Company’s capital requirements to achieve its business objectives, the impact of the COVID-19 pandemic, the Company’s ability to train physical therapists in the supervision of the use of the PoNS Treatment, the Company’s ability to secure contracts with rehabilitation clinics, the Company’s ability to obtain national Medicare coverage and to obtain a reimbursement code so that the PoNS device is covered by Medicare and Medicaid, the Company’s ability to build internal commercial infrastructure, secure state distribution licenses, build a commercial team and build relationships with Key Opinion Leaders, neurology experts and neurorehabilitation centers, market awareness of the PoNS device, future clinical trials and the clinical development process, manufacturing and supply chain risks, the product development process and FDA regulatory submission review and approval process, other development activities, ongoing government regulation, and other risks detailed from time to time in the “Risk Factors” section of the Company’s Annual Report on Form 10-K for the year ended December 31, 2020, its Quarterly Report on Form 10-Q for the quarter ended September 30, 2021 and its other filings with the United States Securities and Exchange Commission and the Canadian securities regulators, which can be obtained from either at www.sec.gov or www.sedar.com.

The reader is cautioned not to place undue reliance on any forward-looking statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company assumes no obligation to update any forward-looking statement or to update the reasons why actual results could differ from such statements except to the extent required by law.

Investor Relations Contact

Lisa M. Wilson, In-Site Communications, Inc.
T: 212-452-2793
E: lwilson@insitecony.com

Be Best Blockchain – Melania Trumps NFTs

Posted on by Admin 


	Image Source: Melania Trump Facebook

Melania Trump Moves into NFT Market to Further “Be Best” Goals

 

Melania Trump announced Thursday (December 16) that she has been eyeballing the NFT art business. She will be offering her first non-fungible token, Melania’s Vision, through December 31st on Solana. Melania joins other celebrities like Tiger Woods, Ellen DeGeneres and Snoop Dogg that have dabbled in this Blockchain medium.

In her official statement, the former first lady said, “I am proud to announce my new NFT endeavor, which embodies my passion for the arts, and will support my ongoing commitment to children through my Be Best initiative.”  She confirmed in her statement that she is starting a platform that will “release NFTs in regular intervals.

 

Trump’s first NFT will be available for purchase until Dec. 31. The NFT, titled “Melania’s Vision,” was first created in watercolor paint and depicts Mrs. Trump’s eyes. It is priced at one SOL, a cryptocurrency that runs on the Solana blockchain, currently valued at around $180. The image will also include an audio recording, a “message of hope” from Melania Trump.

A portion of the proceeds from the NFT sales will “assist children aging out of the foster care system by way of economic empowerment and with expanded access to resources needed to excel in the fields of computer science and technology,” the statement said. The former first lady introduced the Be Best initiative in 2018, during her husband’s term in office. It initially focused on three main “pillars,” well-being, social media use, and opioid abuse among children.

Some of the more high-profile NFTs after Beeple’s The First 5000 Days made headlines include: Jack Dorsey’s digital version of his first tweet, which sold as an NFT for more than $2.9 million, and the viral 2007 video “Charlie Bit My Finger” fetched more than $760,000 in May. Earlier this week, a previously unheard demo track Whitney Houston recorded at age 17, sold as an NFT for $999,999.

 

Suggested Reading:



Trump Media SPAC Merger Details

Tradestation and Trump Media aren’t the Only Hot SPAC Stories





NFT Fractional Ownership and Metaverse Museums

NFT Collectible Marketplace for DRAFTKINGS

 

Sources:

https://melaniatrump.com/eyes-nft

https://explorer.solana.com/address/7CC4YrazfBqr2FMEWEar1fmbP3kULzMfrvW8KDPtfT6W

https://twitter.com/MELANIATRUMP/status/1471468919810670603/photo/1

https://www.lofficielusa.com/pop-culture/celebrities-on-the-crypto-art-craze

https://finance.yahoo.com/news/latest-nft-art-melania-trumps-224641936.html

 

Stay up to date. Follow us:

 

Seanergy Maritime (SHIP) – Another Refinancing Lined Up

Posted on by Admin

Friday, December 17, 2021

Seanergy Maritime (SHIP)
Another Refinancing Lined Up

Seanergy Maritime Holdings Corp. is the only pure-play Capesize shipping company listed in the US capital markets. Seanergy provides marine dry bulk transportation services through a modern fleet of Capesize vessels. Upon delivery of the M/V Dukeship, the Company’s operating fleet will consist of 17 Capesize vessels with an average age of 11.5 years and aggregate cargo carrying capacity of approximately 3,011,083 dwt. The Company is incorporated in the Marshall Islands and has executive offices in Glyfada, Greece. The Company’s common shares trade on the Nasdaq Capital Market under the symbol “SHIP”, its Class A warrants under “SHIPW” and its Class B warrants under “SHIPZ”.

Poe Fratt, Senior Research Analyst, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

    Geniuship debt refinanced on favorable terms. High cost debt of $20 million secured by the Geniuship and Gloriuship Capes will be partially refinanced with a new five-year loan of $15 million secured by the Geniuship priced at Libor plus 350 basis points. Positive impact from extending out the maturity by 1.5 years and reducing interest expense by ~600 basis points, or $0.9 million in 2022. Pro forma for refinancing, total debt is ~$243 million and cash is ~$45 million.

    Transportation & Logistics online forum presentation by CEO Stamatis Tsantanis and CFO Stavros Gyftakis highlighted the substantial progress this year.  The fleet expansion, debt financings, 1Q2021 equity offering and January debt restructuring, in addition to a $17 million buy back program, are solid examples of better execution and improved financials …



This research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary.  Proper due diligence is required before making any investment decision. 

Endeavour Silver (EXK)(EDR:CA) – Drilling Programs Yield Successful Outcomes to Support Growth Objectives

Posted on by Admin

Friday, December 17, 2021

Endeavour Silver (EXK)(EDR:CA)
Drilling Programs Yield Successful Outcomes to Support Growth Objectives

As of April 24, 2020, Noble Capital Markets research on Endeavour Silver is published under ticker symbols (EXK and EDR:CA). The price target is in USD and based on ticker symbol EXK. Research reports dated prior to April 24, 2020 may not follow these guidelines and could account for a variance in the price target.

Endeavour Silver Corp is a precious metal mining company. The company is primarily engaged in silver mining and owns three high-grade, underground, silver-gold mines in Mexico. Its other business activities include acquisition, exploration, development, extraction, processing, refining and reclamation. The company is organized into four operating mining segments, Guanacevi, Bolanitos, El Cubo, and El Compas, which are located in Mexico as well as Exploration and Corporate segments. Its Exploration segment consists of projects in the exploration and evaluation phases in Mexico and Chile.

Mark Reichman, Senior Research Analyst of Natural Resources, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

    Recent drilling results. Endeavour recently disclosed drilling results associated with the Guanacevi and Bolanitos mines, and the Parral exploration project. Drilling programs at existing mines are intended to support reserve replacement and resource expansion, while drilling at Parral builds on an existing mineral resource estimate.

    Extending the life of existing mines.  At Guanacevi, underground drilling continues to expand extensions of the El Curso and the Santa Cruz South (SCS) ore bodies. Through October, the company completed 38 holes, representing more than 14,000 meters of drilling, at Guanacevi. Since the beginning of the year, over 11,500 meters in 59 holes have been drilled at Bolanitos intersecting multiple …



This research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary.  Proper due diligence is required before making any investment decision. 

Digerati Technologies Reports 143% Revenue Growth to $3.777 Million for First Quarter FY2022

Posted on by Admin




Digerati Technologies Reports 143% Revenue Growth to $3.777 Million for First Quarter FY2022

Research, News, and Market Data on Digerati Technologies

 

– Non-GAAP Operating EBITDA of $0.691 Million –
– Gross Profit of $2.287 Million –
– Strong Gross Margin Improvement to 60.6% –

SAN ANTONIO, TX (GlobeNewswire) – December 15, 2021 – Digerati Technologies, Inc. (OTCQB: DTGI) (“Digerati” or the “Company”), a provider of cloud services specializing in UCaaS (Unified Communications as  a Service) solutions for the small to medium-sized business (“SMB”) market, announced today financial results  for the three months ended October 31, 2021, the Company’s first quarter for its Fiscal Year 2022. 

Key Financial Highlights for the First Quarter Fiscal Year 2022 (Ended October 31, 2021) 

  • Revenue increased by 143% to $3.777 million compared to $1.552 million for Q1 FY2021.
  •  Gross profit increased 184% to $2.287 million compared to $0.804 million for Q1 FY2021.
  •  Gross margin increased to 60.6% compared to 51.8% for Q1 FY2021.
  • Non-GAAP Adjusted EBITDA income improved to $0.317 million, excluding all non-cash items and one-time transactional expenses, compared to Adjusted EBITDA income of $0.058 million for Q1FY2021.
  • Non-GAAP operating EBITDA (OPCO EBITDA) improved to income of $0.691 million, excluding corporate expenses, compared to a non-GAAP operating EBITDA of $0.242 million for Q1 FY2021.

Arthur L. Smith, CEO of Digerati, commented, “I commend our team for continuing to execute successfully on  our plan and delivering on solid financial improvements in our first quarter of FY2022. This is reflected in strong  top-line revenue growth of 143%, an increase in gross margin, and improved Adjusted EBITDA results. With a  solid foundation in Florida and Texas, we believe Digerati is well positioned to continue executing on its business  plan and deliver on organic and acquisition growth in a very fragmented market.” 

Antonio Estrada, CFO of Digerati, stated, “Our financial disciplines remain strong since acquiring Nexogy and  ActivePBX in FY2021. Although most of the integration related to these acquisitions is complete, we continue  to streamline cost structures and integrate systems that we anticipate will result in improved financial results in  the future. We look forward to replicating this type of success with additional targeted and accretive acquisitions.” 

Three Months ended October 31, 2021 Compared to Three Months ended October 31, 2020 

Revenue for the three months ended October 31, 2021 was $3.777 million, an increase of $2.225 million or 143% compared to $1.552 million for the three months ended October 31, 2020. The increase in revenue between  periods is primarily attributed to the consolidation of the closed acquisitions of Nexogy and ActivePBX during  the period. 

Gross profit for the three months ended October 31, 2021 was $2.287 million, resulting in a gross margin of  60.6%, compared to $0.804 million and 51.8% for the three months ended October 31, 2020. The increase in gross margin is primarily due to the addition of high-margin revenue associated with Nexogy’s and ActivePBX’s  UCaaS product line.  

Selling, General and Administrative expenses (excluding legal and professional fees) for the three months ended  October 31, 2021 increased by $0.777 million, or 77%, to $1.788 million compared to $1.011 million for the three  months ended October 31, 2020. The increase in SG&A is attributed to the consolidation of the closed acquisitions  of Nexogy and ActivePBX. 

Operating loss for the three months ended October 31, 2021, was $0.580 million, an improvement of $0.046 million or 7%, compared to $0.626 million for the three months ended October 31, 2020. 

Adjusted EBITDA income for the three months ended October 31, 2021, was $0.317 million, an improvement of  $0.259 million, compared to an adjusted EBITDA income of $0.058 million for the three months ended October 31, 2020. In accordance with SEC Regulation G, the non-GAAP measurement of Adjusted EBITDA has been  reconciled to the nearest GAAP measurement, which can be viewed under the heading “Reconciliation of Net  Loss to Adjusted EBITDA” in the financial table included in this press release. 

Of note were the following non-cash expenses associated with the three months ended October 31, 2021. The  Company recognized stock-based compensation and warrant expense of $0.024 million and depreciation and  amortization expense of $0.492 million. Gain on derivative instruments was $4.433 million for the three months ended October 31, 2021. 

Non-GAAP operating EBITDA (OPCO EBITDA) for the three months ended October 31, 2021 improved to  income of $0.691 million, excluding corporate expenses, compared to a non-GAAP operating income of $0.242 million for the three months ended October 31, 2020. 

Net income for the three months ended October 31, 2021, was $2.419 million, an increase of $3.145 million, as  compared to a net loss of $0.726 million, for the three months ended October 31, 2020. The resulting Basic EPS  for the three months ended October 31, 2021 was $0.02, as compared to a Basic EPS loss of ($0.01) for the three  months ended October 31, 2020. 

At October 31, 2021, Digerati had $1.646 million of cash. 

Use of Non-GAAP Financial Measurements 

The Company believes that EBITDA (earnings before interest, taxes, depreciation and amortization) is useful to  investors because it is commonly used in the cloud communications industry to evaluate companies on the basis  of operating performance and leverage. Adjusted EBITDA provides an adjusted view of EBITDA that takes into  account certain significant non-recurring transactions, if any, such as impairment losses and expenses associated  with pending acquisitions, which vary significantly between periods and are not recurring in nature, as well as  certain recurring non-cash charges such as changes in fair value of the Company’s derivative liabilities and stock based compensation. The Company also believes that Adjusted EBITDA provides investors with a measure of  the Company’s operational and financial progress that corresponds with the measurements used by management  as a basis for allocating resources and making other operating decisions. Although the Company uses Adjusted  EBITDA as one of several financial measures to assess its operating performance, its use is limited as it excludes  certain significant operating expenses. Non-GAAP operating EBITDA (OPCO EBITDA) is useful to investors  because it reflects EBITDA for the core operation of the business excluding corporate expenses, non-cash  expenses and transactional expenses. EBITDA, Adjusted EBITDA, and Non-GAAP operating EBITDA are not  intended to represent cash flows for the periods presented, nor have they been presented as an alternative to  operating income or as an indicator of operating performance and should not be considered in isolation or as a  substitute for measures of performance prepared in accordance with accounting principles generally accepted in  the United States of America (“GAAP”). In accordance with SEC Regulation G, the non-GAAP measurements

in this press release have been reconciled to the nearest GAAP measurement, which can be viewed under the heading “Reconciliation of Net Loss to Adjusted EBITDA” in the financial table included in this press release. 

About Digerati Technologies, Inc. 

Digerati Technologies, Inc. (OTCQB: DTGI) is a provider of cloud services specializing in UCaaS (Unified  Communications as a Service) solutions for the business market. Through its operating subsidiaries T3  Communications (T3com.com) and Nexogy (Nexogy.com), the Company is meeting the global needs of  businesses seeking simple, flexible, reliable, and cost-effective communication and network solutions including  cloud PBX, cloud telephony, cloud WAN, cloud call center, cloud mobile, and the delivery of digital oxygen on  its broadband network. The Company has developed a robust integration platform to fuel mergers and acquisitions  in a highly fragmented market as it delivers business solutions on its carrier-grade network and Only in the  Cloud™. For more information, please visit www.digerati-inc.com or follow DTGI on LinkedIn, Twitter and  Facebook.  

Forward-Looking Statements 

The information in this news release includes certain forward-looking statements that are based upon assumptions  that in the future may prove not to have been accurate and are subject to significant risks and uncertainties,  including statements related to the future financial performance of the Company. Although the Company believes  that the expectations reflected in the forward-looking statements such as anticipated improvement in financial  results and delivering on organic and acquisition growth in a very fragmented market, are reasonable, it can give  no assurance that such expectations or any of its forward-looking statements will prove to be correct. Factors that  could cause results to differ include, but are not limited to, our inability to source suitable acquisition targets,  failure to execute growth strategies, lack of product development and related market acceptance, the impact of  competitive services and pricing, general economic conditions, and other risks and uncertainties described in the  Company’s periodic filings with the Securities and Exchange Commission. 

Facebook: Digerati Technologies, Inc. 
Twitter: @DIGERATI_IR 
LinkedIn: Digerati Technologies, Inc.  

Investors 

The Eversull Group 
Jack Eversull  
jack@theeversullgroup.com 
(972) 571-1624 

ClearThink 
Brian Loper 
bloper@clearthink.capital 
(347) 413-4234

Pangaea Logistics (PANL) – Tune Into Virtual Transportation & Logistics Forum

Posted on by Admin

Thursday, December 16, 2021

Pangaea Logistics (PANL)
Tune Into Virtual Transportation & Logistics Forum

Pangaea Logistics Solutions Ltd and its subsidiaries provide seaborne drybulk transportation services. It transports drybulk cargos including grains, coal, iron, ore, pig, iron, hot briquetted iron, bauxite, alumina, cement clinker, dolomite and limestone. The firm’s services include cargo loading, cargo discharge, vessel chartering, voyage planning and technical vessel management. The company derives all of its revenues from contracts of affreightment, voyage charters and time charters. Its strategy depends on focusing on increasing strategic contracts of affreightment, expanding capacity and flexibility by increasing its owned fleet and increasing backhaul focus and fleet efficiency.

Poe Fratt, Senior Research Analyst, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

    Tune in to hear about Pangaea Logistics at today’s Transportation & Logistics online forum. CEO Mark Filanowski, Managing Director Mads Boye Peterson and CFO Gianni Del Signore will present at 2:00pm EST. Free registration is available at channelchek.vercel.app

    Presentation should highlight positive 2021 developments.  We expect a positive view on the dry bulk market fundamentals, especially for the Ice Class sector. There are many reasons that PANL remains well positioned, including a consistent commercial strategy that adds value in different market environments, a leading Ice Class market position, substantial progress on renewing and expanding the …



This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary.  Proper due diligence is required before making any investment decision. 

Seanergy Maritime (SHIP) – Tune Into Virtual Transportation & Logistics Forum

Posted on by Admin

Thursday, December 16, 2021

Seanergy Maritime (SHIP)
Tune Into Virtual Transportation & Logistics Forum

Seanergy Maritime Holdings Corp. is the only pure-play Capesize shipping company listed in the US capital markets. Seanergy provides marine dry bulk transportation services through a modern fleet of Capesize vessels. Upon delivery of the M/V Dukeship, the Company’s operating fleet will consist of 17 Capesize vessels with an average age of 11.5 years and aggregate cargo carrying capacity of approximately 3,011,083 dwt. The Company is incorporated in the Marshall Islands and has executive offices in Glyfada, Greece. The Company’s common shares trade on the Nasdaq Capital Market under the symbol “SHIP”, its Class A warrants under “SHIPW” and its Class B warrants under “SHIPZ”.

Poe Fratt, Senior Research Analyst, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

    Tune in to hear about SHIP at today’s Transportation & Logistics online forum. CEO Stamatis Tsantanis and CFO Stavros Gyftakis will present at 11:00am EST. Free registration is available at channelchek.vercel.app

    Presentation highlights should include substantial 2021 progress.  The fleet expansion to 17 Capes and recent completion of the $17 million buy back program are good indications of better execution and an improved financial position. The retirement of convert debt and stock and warrant buy backs limits potential share issuance …



This research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary.  Proper due diligence is required before making any investment decision.